Jaguar Health, Inc.
Tuesday, February 27, 2024
Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases.
CEO/Top Company Official
Lead Product in Development
Mytesi (crofelemer) is Jaguar's FDA-approved antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Crofelemer is in development for a variety of follow-on indications, including the rare disease Short Bowel Syndrome and Microvillus Inclusion Disease (a Congenital Diarrheal Disorder); as well as for Cancer Therapy-related Diarrhea (CTD) and Inflammatory Bowel Disease. Additionally, NP-300, a Jaguar drug that has a similar physiological anti-secretory mechanism of action (MOA) to crofelemer, is under development for the symptomatic relief and treatment of diarrhea from bacterial, viral, and parasitic infections including Vibrio cholerae, the bacterium that causes cholera. CTD is the company's primary development focus. Comprehensive results for the company’s placebo-controlled pivotal Phase 3 OnTarget trial for prophylaxis (prevention) of diarrhea in adult cancer patients receiving targeted therapy with or without standard chemotherapy are expected in Q1 2024. OnTarget is a first-of-its-kind, 24-week (two 12-week stages) clinical trial with a primary endpoint based on patient-reported outcomes that address the highly neglected and unmet burden of cancer therapy-related diarrhea, an indication Napo also refers to as preventive treatment of chemotherapy-induced overactive bowel (CIOB) – which includes symptoms such as chronic and/or episodic debilitating diarrhea (loose and/or watery stools), urgency, bowel incontinence and abdominal pain and discomfort.
Development Phase of Primary Product